PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Board Posted on April 9, 2024January 18, 2026 by edgover
PulseSight launches with gene therapy platform targeting age-related blindness Posted on March 4, 2024January 18, 2026 by edgover
PulseSight Therapeutics launches with focus on non-viral gene therapies Posted on February 29, 2024January 18, 2026 by edgover
PulseSight Therapeutics Launches With Age-Related Macular Disease Gene Therapy Pipeline Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics launches to advance non-viral gene therapies Posted on February 28, 2024January 18, 2026 by edgover
[Funding alert] Paris-based PulseSight Therapeutics Secures an Undisclosed Amount in Seed Funding Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics launches to advance non-viral gene therapies Posted on February 28, 2024January 18, 2026 by edgover
Launch of PulseSight Therapeutics: advancing non-viral gene therapy for eye diseases Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics Will Develop Next Generation Eye Gene Therapies Posted on February 28, 2024January 18, 2026 by edgover
![[Funding alert] Paris-based PulseSight Therapeutics Secures an Undisclosed Amount in Seed Funding](https://pulsesight.com/wp-content/uploads/2026/01/Paris-based-PulseSight-Therapeutics-Secures-an-Undisclosed-amount-in-Seed-Funding.webp)
